Search results for "EMC"
showing 10 items of 369 documents
Botāniskā dārza sekcijas “Augu daudzveidības pētījumi ex situ” un “Augu selekcija un introdukcija” tēžu krājums
2022
Latvijas Universitātes 80. starptautiskās zinātniskās konferences Botāniskā dārza sekcijas “Augu daudzveidības pētījumi ex situ” un “Augu selekcija un introdukcija” referāti tika nolasīti 2022. gada 1. februārī plkst. 13:00 tiešsaistē.
Abstract C75: Overcoming KRAS/LKB1 mutant NSCLC resistance to BET bromodomain inhibitors with gemcitabine or Mcl-1 inhibition
2015
Abstract The purpose of our study was to define a method and mechanism for overcoming the resistance of clinically relevant KRAS-mutant/LKB1-deficient NSCLC cells to the BET-bromodomain inhibitor JQ1. LKB1 (Serine/threonine kinase 11) is mutated with loss of function in conjunction with mutated KRAS in 7-10% of NSCLC. Importantly, KRAS-mutant/LKB1-deficiency is associated with tumor aggressiveness and poor survival in human patients as well as in genetically engineered mouse models. Indeed, although the BET bromodomain inhibitor JQ1 dramatically reduces tumor volume in KRAS mutant mice, it has little effect in KRAS-mutant/LKB1-deficient mice. BET bromodomain proteins are chromatin readers t…
National & International UID Portfolio
2014
In this survey, starting from the research activities carried out by the LAAC - Laboratory of Archaeology and Architecture of the Granada city, special focus is placed on the reconstruction of one of the most emblematic and symbolic buildings of the Algerian culture, the mosque and the minaret of the City of Mansoura (Tlemcen): starting from a photographic campaign that was also conducted remotely, it has been assumed to rebuilt virtually partially destroyed building as a symbol and a memory of its ancient splendour.
Metformin influences drug sensitivity in pancreatic cancer cells
2018
Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10% after diagnosis and treatment. Pancreatic cancer has been associated with type II diabetes as the frequency of recently diagnosed diabetics that develop pancreatic cancer within a 10-year period of initial diagnosis of diabetes in increased in comparison to non-diabetic patients. Metformin is a very frequently prescribed drug used to treat type II diabetes. Metformin acts in part by stimulating AMP-kinase (AMPK) and results in the suppression of mTORC1 activity and the induction o…
Dzieje organów w kościele parafialnym w Niemczy
2018
Pierwsze wzmianki o organach w kościele parafialnym w Niemczy pochodzą z przełomu XVI i XVII wieku. W latach 1597–1598 niewielki instrument wybudował Abraham Grasse. W 1617 roku ten sam organmistrz postawił nowe organy, liczące sześć głosów w manuale i trzy w pedale. Strawił je pożar w 1633 roku. W 1648 roku do odbudowanego kościoła zakupiono używany pozytyw. W 1725 roku świątynia wzbogaciła się o 20-głosowe organy wybudowane przez Ignatzego Mentzla. Służyły one parafii do 1852 roku, wówczas zamknięto, a następnie rozebrano kościół. Organy znajdujące się w obecnej świątyni pochodzą z 1866 roku i są dziełem Gottfrieda Riemera z Brzegu. Miały pierwotnie 18 głosów i mechaniczną trakturę rejest…
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
2002
<i>Objective:</i> This study was designed to determine the maximum tolerable dose (MTD) of gemcitabine plus docetaxel, both given on a weekly schedule, in patients with pretreated metastatic breast cancer (MBC). <i>Methods:</i> Heavily pretreated patients with MBC, aged 18–75 years with World Health Organization performance status of 0–2 were enrolled. Three escalating weekly doses of docetaxel (30, 35 and 40 mg/m<sup>2</sup>) followed by a weekly fixed dose of gemcitabine, 800 mg/m<sup>2</sup>, were administered on days 1, 8 and 15 of a 28-day cycle. Dose-limiting toxicity (DLT) included grade >3 hematologic toxicity and grade >2 stomat…
Determination of periodontopathogens in patients with cri du chat syndrome
2013
Objectives: Cri du chat syndrome is a genetic alteration associated with some oral pathologies. However, it has not been described previously any clinical relationship between the periodontal disease and the syndrome. The purpose of this comparative study was to compare periodontopathogenic flora in a group with Cri du chat syndrome and another without the síndrome, to assess a potential microbiological predisposition to suffer a periodontitis. Study Design: The study compared nineteen subjects with Cri du chat Syndrome with a control group of nineteen patients without it. All patients were clinically evaluated by periodontal probing, valuing the pocket depth, the clinical attachmente level…
Effects of photodynamic therapy in periodontal treatment: A randomized, controlled clinical trial
2017
Aim To evaluate the effects of photodynamic therapy (PDT) in the nonsurgical treatment of chronic periodontitis. Materials and methods A randomized, single-blind, controlled, parallel-group clinical trial was performed. Sixty patients were enrolled: 20 healthy controls and 40 patients with periodontitis. The 40 patients were randomized for scaling and root planing (SRP) or SRP+PDT. Periodontal (plaque index, probing depth, clinical recession, clinical attachment level, bleeding on probing, and gingival crevicular fluid volume, corresponding to 381 vs 428 critical sites), microbiological (Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Tannerella forsythia, Treponema dentico…
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic aden…
2020
Abstract Background Chemotherapy is effective in metastatic pancreatic adenocarcinoma (mPA), but new approaches are still needed to improve patients' survival and quality of life. We have previously published good efficacy and tolerability results on a sequential treatment strategy of gemcitabine followed by an intensified FOLFIRI (5FU+irinotecan) regimen. In the present study, we evaluated the same sequence but replaced gemcitabine by the new gemcitabine + nab-paclitaxel standard first-line combination. Patients and methods We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status 0–2 to alternately receive gemcitab…
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer
2005
Abstract BACKGROUND AND AIMS: oxaliplatin in combination with folinic acid (FA) and infusional 5-fluorouracil (5-FU) has shown significant anti-tumor activity in gastric cancer patients (FOLFOX). Previous studies have shown that gemcitabine (GEM), a new fluorinated anti-metabolite, enhances the individual anti-tumor activity of either 5-FU or oxaliplatin. We have therefore designed a multi-center phase II trial in order to test a novel GEM+FOLFOX-4 regimen in patients with metastatic gastric cancer. METHODS: we enrolled 36 patients, 28 males and 8 females, with an average age of 64.4 years (range 37-78), who received bi-weekly treatment with GEM (1,000 mg/m2 on day 1), levo-FA (100 mg/m2 on…